222 related articles for article (PubMed ID: 24316262)
1. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
[TBL] [Abstract][Full Text] [Related]
2. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
[TBL] [Abstract][Full Text] [Related]
3. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
[TBL] [Abstract][Full Text] [Related]
4. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
Foster GR; Hézode C; Bronowicki JP; Carosi G; Weiland O; Verlinden L; van Heeswijk R; van Baelen B; Picchio G; Beumont M
Gastroenterology; 2011 Sep; 141(3):881-889.e1. PubMed ID: 21699786
[TBL] [Abstract][Full Text] [Related]
5. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
[TBL] [Abstract][Full Text] [Related]
6. Telaprevir for previously treated chronic HCV infection.
McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
[TBL] [Abstract][Full Text] [Related]
7. Telaprevir for retreatment of HCV infection.
Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
[TBL] [Abstract][Full Text] [Related]
8. Telaprevir for previously untreated chronic hepatitis C virus infection.
Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
[TBL] [Abstract][Full Text] [Related]
9. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
Marcellin P; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Serfaty L; De Backer K; Van Heeswijk R; Luo D; Picchio G; Beumont M
Gastroenterology; 2011 Feb; 140(2):459-468.e1; quiz e14. PubMed ID: 21034744
[TBL] [Abstract][Full Text] [Related]
10. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
Wedemeyer H; Forns X; Hézode C; Lee SS; Scalori A; Voulgari A; Le Pogam S; Nájera I; Thommes JA
PLoS One; 2016; 11(1):e0145409. PubMed ID: 26752189
[TBL] [Abstract][Full Text] [Related]
11. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
Perry CM
Drugs; 2012 Mar; 72(5):619-41. PubMed ID: 22439668
[TBL] [Abstract][Full Text] [Related]
12. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
[TBL] [Abstract][Full Text] [Related]
13. Preliminary study of two antiviral agents for hepatitis C genotype 1.
Lok AS; Gardiner DF; Lawitz E; Martorell C; Everson GT; Ghalib R; Reindollar R; Rustgi V; McPhee F; Wind-Rotolo M; Persson A; Zhu K; Dimitrova DI; Eley T; Guo T; Grasela DM; Pasquinelli C
N Engl J Med; 2012 Jan; 366(3):216-24. PubMed ID: 22256805
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
15. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
Forestier N; Reesink HW; Weegink CJ; McNair L; Kieffer TL; Chu HM; Purdy S; Jansen PL; Zeuzem S
Hepatology; 2007 Sep; 46(3):640-8. PubMed ID: 17879366
[TBL] [Abstract][Full Text] [Related]
16. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
18. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
Burney T; Dusheiko G
Expert Rev Anti Infect Ther; 2011 Feb; 9(2):151-60. PubMed ID: 21143041
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
Shiffman ML; Suter F; Bacon BR; Nelson D; Harley H; Solá R; Shafran SD; Barange K; Lin A; Soman A; Zeuzem S;
N Engl J Med; 2007 Jul; 357(2):124-34. PubMed ID: 17625124
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
